Longevity research is attracting ever larger sums: in June 2026, the San Francisco start-up NewLimit closed a financing round of 435 million US dollars at a valuation of 3.1 billion dollars. With the money, the company wants to bring into the clinic a therapy intended to rejuvenate aged liver cells epigenetically.
Who is behind it?
NewLimit was founded in 2021 by Coinbase CEO Brian Armstrong, investor Blake Byers and biologist Jacob Kimmel. The current round was led by Founders Fund; participants include Thrive Capital, Kleiner Perkins and – notably – Eli Lilly Ventures, the investment arm of one of the world’s largest pharmaceutical companies.
The approach
Like other companies in the sector, NewLimit is relying on epigenetic reprogramming: certain transcription factors are intended to make old cells adopt a younger gene activity pattern again. Instead of the well-known Yamanaka factors, the company uses its own combinations of fewer than ten factors.
The instructions for these factors are administered as mRNA in lipid nanoparticles – the same technology that was used in the mRNA vaccines. Lipid nanoparticles accumulate particularly in the liver. Unlike virus-based gene vectors, the mRNA is broken down again after a short time, which could limit the duration of the effect and make it more controllable.
Stage of development
- According to the company, only preclinical data from cell and mouse models are available so far.
- A first clinical trial is planned for 2027 – not against “ageing” but against fatty liver disease (MASLD).
- Observers expect the first trial data in two to three years at the earliest.
Assessment
The funding shows how heavily investors and the pharmaceutical industry are now betting on reprogramming. At the same time, none of these technologies has yet shown in humans that it actually rejuvenates organs. Choosing a specific disease such as fatty liver as the first target is typical – regulatory authorities do not yet recognise “ageing” as a treatable indication. In addition, many details come from company statements and media reports, not from peer-reviewed publications.
Note: This article is for general information only and does not constitute investment advice.
Leave a Reply